Skip to main content

real-world evidence

Conference Coverage
12/06/2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study...
12/06/2020
Journal of Clinical Pathways